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Frampton et al. demonstrate an increased viral load, but not severity of disease or 28-day mortality  in 
hospitalised patients infected by the B.1.1.7 variant of the SARS Cov-2 virus.1 In contrast, we found 
slightly different results when assessing the risk of morbidity and mortality in a matched case-control 
study of 60 patients – 30 hospitalised by infection with the B.1.1.7 variant and 30 patients by non-
B.1.1.7 variants. Cases were matched for admission period and age band. Clinical severity scores, 
requirement for ventilation, treatments received and 28-day mortality were compared between groups 
from anonymised retrospective data, using Wilcoxon rank sum and Chi-squared or Fisher’s exact 
tests.  
 
Our findings (Table 1) showed consistent and rational evidence that patients infected with the B.1.1.7 
variant developed more serious disease -  higher clinical severity (e.g., higher NEWS value, lower 
ROX index), higher levels of supplemental oxygen requirement and mechanical ventilation, more 
often received approved treatments for SARS CoV-2 infection (e.g., dexamethasone, remdesivir and 
tocilizumab) and more serious clinical outcomes (i.e., higher 28-day mortality, WHO clinical 
progression scale). Although our results show a tendency towards severe disease with B.1.1.7 
infection , it is likely that our study was under-powered as statistical significance was only achieved 
for more patients requiring dexamethasone in the B.1.1.7 variant group. Nevertheless, they echo the 
findings of Challen et al., who studied a younger population with likely less comorbidity and found a 
64% increase in 28-day mortality following community infection with the B.1.1.7 variant (control 
group, 0·26%; B.1.1.7 variant group, 0·41%).2 
 
We believe that the identification of any increased morbidity and mortality risks caused by SARS-
CoV-2 variants of concern requires adequately powered studies utilising a combination of community 
and hospital PCR swabs, examination of disease severity using more detailed clinical severity scores 
with physiological measures and the impact of viral load, novel treatments and vaccinations. For the 
purposes of future case-control studies, we estimate a post-hoc sample size of 234 patients in each 
group is required for an effect size of +11·4% on 28-day mortality for a baseline of 20·7% at 80% 
power with 5% significance. We propose the jury for mortality risk for B.1.1.7 infections currently 
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Table 1. Summary of results between cases of SARS-Cov-2 infection with B.1.1.7 variant compared to non-B.1.1.7 variants.   
 n Infection with B.1.1.7 variant n Infection with a non-B.1.1.7 
variant 
p-value 
Demographics      
Date of first positive PCR swab 30 03/12/20 – 20/12/20 30 10/10/20 – 20/12/20  
Age (years)  77 (59-88)  79 (59-87) 0·976 
Male sex (%)  50%  60% 0·436 
Number of comorbidities   2 (1-3)  2 (1-3) 0·845 
White ethnicity (%)  26/30 (87%)  30/30 (100%)  
Clinical severity scores      
National Early Warning Score 2 (NEWS2)*: 

















ROX index:  
At presentation  
















Sequential Organ Failure Assessment (SOFA) score: 
At presentation 
















4C Mortality Score: 
At presentation 
















Maximum ventilatory support received 30  30  0·265 
Mechanical ventilation   10·0%  3·3%  
Non-invasive ventilation  0·0%  3·3%  
Standard oxygen therapy   60·0%  46·7%  
No supplemental oxygen required  30·0%  46·7%  
Treatment received      
Dexamethasone 18 13 (72·2%) 24 10 (41·7%) 0·049** 
Remdesivir 14 2 (14·3%) 22 1 (4·6%) 0·547 
Anticoagulation 24 4 (16·7%) 30 8 (26·6%) 0·380 
 
Unless stated, all results are the median (interquartile range). 
FiO2 = fraction of inspired oxygen) 
* The NEWS2 score was not calculated at maximum FiO2.  







Tocilizumab 28 1 (3·6%) 28 0 (0·0%) 1·000 
28-day mortality (95% confidence interval) 28 32·1%  
(17·9-50·7%) 
29 20·7%  
(9·8-38·4%) 
0·326 
Patients with a severe clinical outcome (%)$ 
$ WHO scale by day 14 after symptom onset or after first 
positive SARS-CoV-2 PCR of at least 6 or patient death 
within 28 days. 
 11/30 (36·7%)  8/30 (26.7%) 0·405 
